NASDAQ:GILD - Gilead Sciences Stock Price, News, & Analysis

Get Started

$66.76 -0.83 (-1.23 %)

(As of 02/20/2019 03:31 AM ET)

Previous Close$67.59

Today's Range$66.65 - $67.77

52-Week Range$60.32 - $82.71

Volume6.39 million shs

Average Volume7.90 million shs

Market Capitalization$86.36 billion

P/E Ratio10.86

Dividend Yield3.37%

Beta1.19

Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for blood cancer; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; AELIX Therapeutics S.L.; TARGET PharmaSolutions, Inc.; Scholar Rock Holding Corporation; and Agenus Inc. The company was founded in 1987 and is headquartered in Foster City, California.

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:GILD

Previous Symbol

CUSIP37555810

Webwww.gilead.com

Phone650-574-3000

Debt

Debt-to-Equity Ratio1.09

Current Ratio3.36

Quick Ratio3.29

Price-To-Earnings

Trailing P/E Ratio10.86

Forward P/E Ratio10.72

P/E Growth4.15

Sales & Book Value

Annual Sales$22.13 billion

Price / Sales3.90

Cash Flow$9.7460 per share

Price / Cash Flow6.85

Book Value$16.65 per share

Price / Book4.01

Profitability

EPS (Most Recent Fiscal Year)$6.15

Net Income$5.46 billion

Net Margins24.65%

Return on Equity37.03%

Return on Assets12.44%

Miscellaneous

Employees10,000

Outstanding Shares1,293,620,000

Market Cap$86.36 billion

OptionableOptionable

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Monday, February 4th. Shareholders of record on Friday, March 15th will be paid a dividend of $0.63 per share on Thursday, March 28th. This represents a $2.52 annualized dividend and a yield of 3.77%. The ex-dividend date is Thursday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.57. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) released its earnings results on Monday, February, 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.70 by $0.26. The biopharmaceutical company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The company's quarterly revenue was down 2.6% compared to the same quarter last year. During the same period last year, the company earned $1.78 EPS. View Gilead Sciences' Earnings History.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Gilead Sciences.

What price target have analysts set for GILD?

18 equities research analysts have issued 1-year price objectives for Gilead Sciences' stock. Their forecasts range from $68.00 to $95.00. On average, they anticipate Gilead Sciences' stock price to reach $83.4375 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price. View Analyst Price Targets for Gilead Sciences.

What is the consensus analysts' recommendation for Gilead Sciences?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 8 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

1. According to Zacks Investment Research, "Gilead’s HCV franchise continues to witness slowdown across key markets including the United States. and Europe, reflecting lower sales of Harvoni and Sovaldi as a result of competitive and pricing pressure. The franchise saw a significant plunge in sales due to new competition and fewer patient starts. Also, the HIV franchise faces competition from the likes of Glaxo, among others. While the Kite acquisition surely looks positive given the potential in the CAR T space, the deal looks expensive given the price Gilead paid. Nevertheless, Gilead’s HIV franchise maintains momentum, driven by the continued uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. The FDA approval of Biktarvy has further widened the portfolio. Biktarvy has also been approved in Europe. Shares have outperfomed the industry in the last six months." (1/23/2019)
2. Cantor Fitzgerald analysts commented, ": We are increasing our price target to $88 from $87 and reiterating our Overweight rating. Gilead beat top and bottom line consensus expectations as the Biktarvy launch remains strong in HIV. Our price target is higher by $1/share given revenue trends were slightly more robust than we projected. The company also increased its product revenue guidance to $20.8-21.3B from $20-21B. Product revenues were $5.45B and EPS were $1.84/share. Biktarvy beat expectations by ~$50M, as it reported revenues of $375M. GILD has also benefited from a generic Letairis not entering the market, and it doesn’t expect an entrant in 2018. We have updated our estimates for the quarter." (10/26/2018)
3. Needham & Company LLC analysts commented, "Gilead reported $5.09B 1Q18 total revenue, below our $5.52B and consensus $5.3B ests. Product sales were $5.00B, below our $5.41B est. Gilead continues to lose share to Abbvie in HCV. Trend is worrisome, although mgmt still guiding for market share stabilization mid-2018. HIV sales in 1Q18 also disappointed, reportedly driven by bigger than expected seasonal inventory draw-down and generic TDF. Growth in HIV (i.e. Biktarvy success) is critical. NASH program has not yet distinguished itself, awaiting data from selonsertib Phase 3 trials (1H19) and 48wk combination Phase 2 trials (2020). Yescarta and cell therapy programs are in early stages." (5/2/2018)

Has Gilead Sciences been receiving favorable news coverage?

Media stories about GILD stock have trended somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Gilead Sciences earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.

Are investors shorting Gilead Sciences?

Gilead Sciences saw a decline in short interest in January. As of January 31st, there was short interest totalling 11,548,612 shares, a decline of 14.0% from the January 15th total of 13,429,498 shares. Based on an average daily trading volume, of 7,327,632 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.9% of the company's stock are sold short. View Gilead Sciences' Current Options Chain.

Who are some of Gilead Sciences' key competitors?

Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), BIO-TECHNE (TECH), argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO) and Denali Therapeutics (DNLI).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

Ms. Robin L. Washington, CFO & Exec. VP (Age 56)
Mr. Kevin B. Young, Advisory (Age 61)
Mr. Gregg H. Alton, Interim CEO & Chief Patient Officer (Age 53)
Dr. John G. McHutchison, Exec. VP of Research, Clinical R&D and Chief Scientific Officer
Sung Lee, VP of Investor Relations

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.05%), Oregon Public Employees Retirement Fund (2.24%), Bank of New York Mellon Corp (2.21%), Northern Trust Corp (1.31%), Geode Capital Management LLC (1.30%) and Parnassus Investments CA (0.83%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Which institutional investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Bank of New York Mellon Corp, Canada Pension Plan Investment Board, State Treasurer State of Michigan, BB Biotech AG, First Manhattan Co., Boston Partners and Great West Life Assurance Co. Can. Company insiders that have sold Gilead Sciences company stock in the last year include Gregg H Alton, John C Martin, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Which institutional investors are buying Gilead Sciences stock?

GILD stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, BlackRock Inc., Two Sigma Advisers LP, Los Angeles Capital Management & Equity Research Inc., Geode Capital Management LLC, Bank of Nova Scotia, Assenagon Asset Management S.A. and Mn Services Vermogensbeheer B.V.. View Insider Buying and Selling for Gilead Sciences.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $66.76.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $86.36 billion and generates $22.13 billion in revenue each year. The biopharmaceutical company earns $5.46 billion in net income (profit) each year or $6.15 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is http://www.gilead.com.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)

Community Ranking:		3.5 out of 5 ( )
Outperform Votes:		1,999 (Vote Outperform)
Underperform Votes:		887 (Vote Underperform)
Total Votes:		2,886

MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 2/20/2019 by MarketBeat.com Staff